PHARMACYCLICS INC | 62,30 Euro | -4,44 -6,65 % | |
| WKN: 904042 ISIN: US7169331060 Ticker-Symbol: PY2 | Frankfurt | 23.05.13 | 15:36 Uhr |
Branche PharmaAktienmarkt Sonstige |
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 21.05. | PHARMACYCLICS INC - 8-K, Current Report | 2 | SEC Filings | |
| 13.05. | Pharmacyclics Makes a Move: Up 6.3% | 9 | SmarTrend | |
| 12.05. | Pharmacyclics is Among the Companies in the Biotechnology Industry With the Lowest EBITDA Growth | 7 | SmarTrend | |
| 02.05. | Wider-Than-Expected Loss at Pharmacyclics | 9 | Zacks | |
| 02.05. | Pharmacyclics Management Discusses Q1 2013 Results - Earnings Call Transcript | 1 | Seeking Alpha | |
| 01.05. | Pharmacyclics Reports First Quarter 2013 Results | 37 | PR Newswire | |
| SUNNYVALE, Calif., May 1, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for its three months ended March 31, 2013.
Financial... Mehr lesen zu: Pharmacyclics Reports First Quarter 2013 Results | ||||
| 24.04. | Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call | 33 | PR Newswire | |
| SUNNYVALE, Calif., April 24, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that it will report financial results and recent developments for its... Mehr lesen zu: Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call | ||||
| 18.04. | Pharmacyclics Completes Enrollment of First Phase III Ibrutinib CLL Study - RESONATE' and Announces Completion of Enrollment of Phase II Ibrutinib MCL Study - SPARK | 47 | PR Newswire | |
| SUNNYVALE, Calif., April 18, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that the enrollment target of 350 patients for its Phase III study using ibrutinib monotherapy... Mehr lesen zu: Pharmacyclics Completes Enrollment of First Phase III Ibrutinib CLL Study - RESONATE' and Announces Completion of Enrollment of Phase II Ibrutinib MCL Study - SPARK | ||||
| 18.04. | Pharmacyclics Crosses Above its 10-day MA | 2 | SmarTrend | |
| 16.04. | Amarin, Pharmacyclics, Anthera Pharma, Star Scientific, and Impax Laboratories Under StockCall's Microscope | 58 | PR Newswire | |
| LONDON, April 16, 2013 /PRNewswire/ --
Last year, patents on several blockbuster drugs expired, leading to increasing competition from generic drugs. The trend is expected to continue in 2013. In... Mehr lesen zu: Amarin, Pharmacyclics, Anthera Pharma, Star Scientific, and Impax Laboratories Under StockCall's Microscope | ||||
| 15.04. | Pharmacyclics Earns 4th Milestone | 4 | Zacks | |
| 14.04. | Shares of Pharmacyclics Rank the Lowest in Terms of EBITDA Growth in the Biotechnology Industry | 8 | SmarTrend | |
| 11.04. | PHARMACYCLICS INC - 8-K, Other Events Financial Statements and Exhibits | 2 | SEC Filings | |
| 11.04. | Pharmacyclics Gets Fourth $50 Million Milestone Payment from Janssen | 2 | Euroinvestor | |
| 11.04. | Pharmacyclics Triggers $50M Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study | 1 | Benzinga.com | |
| 11.04. | Pharmacyclics (PCYC) Hits $50M Milestone with RESONATE-2 Enrollment | - | StreetInsider.com | |
| 11.04. | Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study | 70 | PR Newswire | |
| SUNNYVALE, Calif., April 11, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that the Phase III clinical trial (RESONATE'-2), a monotherapy trial using ibrutinib versus chlorambucil... Mehr lesen zu: Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study | ||||
| 10.04. | Short Sellers Move Out of Amgen, Celgene, Pharmacyclics | 43 | Benzinga.com | |
| 08.04. | Pharmacyclics Offers Result from Phase II Trial of Ibrutinib | 2 | Benzinga.com | |
| 08.04. | Pharmacyclics (PCYC) Updates on CLL Treatment Ibrutinib Phase II | 1 | StreetInsider.com | |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| PFIZER | 22,397 | -0,35 % | Pfizer spaltet Tierarzneisparte Zoetis endgültig ab |
| MERCK KGAA | 122,15 | -1,41 % | Bernecker.tv: Nikkei erreicht ein neues 5-Jahres-Hoch! Aktien: Yingli, Huaneng Power, Yahoo und Merck ... |
| ARIAD PHARMACEUTICALS | 14,719 | +3,29 % | Ariad's Cancer Drug Iclusig Extends The Gleevec Magic |
| VERTEX PHARMACEUTICALS | 60,45 | +0,04 % | Flagship Partners-backed Syros Pharma taps former Vertex vet as new CSO |
| ALEXION PHARMACEUTICALS | 77,23 | -0,60 % | Alexion setzt ans Kaufniveau zurück |
